tiletamine hydrochloride has been researched along with imatinib mesylate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schwetz, BA | 1 |
| Ishida, T; Izawa, K; Kobayashi, S; Lin, SF; Tojo, A; Tsai, HJ; Umezawa, K; Watanabe, T | 1 |
2 other study(ies) available for tiletamine hydrochloride and imatinib mesylate
| Article | Year |
|---|---|
From the Food and Drug Administration.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents, Second-Generation; Antineoplastic Agents; Arthritis, Psoriatic; Benzamides; Chemical and Drug Induced Liver Injury; Cyclohexanones; Enzyme Inhibitors; Etanercept; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Immunoglobulin G; Infant; Liver Failure; Nitrobenzoates; Orphan Drug Production; Piperazines; Pyrimidines; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Triazoles; Tyrosinemias; United States; United States Food and Drug Administration | 2002 |
Bioimaging analysis of nuclear factor-κB activity in Philadelphia chromosome-positive acute lymphoblastic leukemia cells reveals its synergistic upregulation by tumor necrosis factor-α-stimulated changes to the microenvironment.
Topics: Animals; Antineoplastic Agents; Benzamides; Bone Marrow; Cell Line, Tumor; Cyclohexanones; Disease Progression; Gene Expression Regulation, Leukemic; Genes, Reporter; Humans; Imatinib Mesylate; Luminescent Measurements; Mice; Neoplasm Proteins; NF-kappa B; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recombinant Fusion Proteins; Spleen; Stromal Cells; Transgenes; Transplantation, Heterologous; Tumor Burden; Tumor Microenvironment; Tumor Necrosis Factor-alpha | 2011 |